(Q38229930)

31 August 2017

0 references

Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis (English)

1 reference

31 August 2017

1 reference

1 reference

2

Ngalei Tam

1 reference

31 August 2017

6

Linwei Wu

1 reference

31 August 2017

3

Ronghai Deng

1 reference

31 August 2017

Liya Su

1

1 reference

31 August 2017

Philip Chen

series ordinal

4

1 reference

31 August 2017

Haibo Li

series ordinal

5

1 reference

31 August 2017

publication date

16 July 2014

1 reference

International Urology and Nephrology

31 August 2017

published in

1 reference

31 August 2017

volume

46

1 reference

31 August 2017

issue

10

1 reference

31 August 2017

page(s)

2035-2044

1 reference

Cyclosporin A in patients receiving renal allografts from cadaver donors

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

The natural history of chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

A drug safety evaluation of everolimus in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Apoptosis and treatment of chronic allograft nephropathy with everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Münster

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

The first year renal function as a predictor of long-term graft survival after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

First year renal function as a predictor of kidney allograft outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

mToR inhibitors-induced proteinuria: mechanisms, significance, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Management of side effects of sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Cardiovascular complications after renal transplantation and their prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Influencing factors of new-onset diabetes after a renal transplant and their effects on complications and survival rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

The pros and the cons of mTOR inhibitors in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-014-0783-1

Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus.

21 January 2018

1 reference

12 December 2020

Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation

1 reference

12 December 2020

mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?

1 reference

12 December 2020

Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients

1 reference

12 December 2020

Strategies for the management of adverse events associated with mTOR inhibitors

1 reference

12 December 2020

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

1 reference

12 December 2020

Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients

1 reference

12 December 2020

Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases

1 reference

12 December 2020

Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation

1 reference

12 December 2020

mTOR signaling, function, novel inhibitors, and therapeutic targets.

1 reference

12 December 2020

Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience

1 reference

12 December 2020

Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients

1 reference

12 December 2020

10.1007/S11255-014-0783-1

Identifiers

DOI

1 reference

31 August 2017

1 reference